Gerresheimer stock
Price history
+33.96% over the period1 year: from €23.56 (November 20, 2025) to €31.56 (November 20, 2026), +33.96%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €31.56 |
| October 30, 2026 | €32.04 |
| September 30, 2026 | €28.94 |
| August 31, 2026 | €28.12 |
| July 31, 2026 | €27.54 |
| June 30, 2026 | €27.82 |
| May 29, 2026 | €27.20 |
| April 30, 2026 | €24.54 |
| March 31, 2026 | €19.62 |
| February 27, 2026 | €16.95 |
| January 30, 2026 | €25.22 |
| December 30, 2025 | €27.58 |
| November 28, 2025 | €26.54 |
| November 20, 2025 | €23.56 |
At a glance
The company
Provide drug containment and delivery solutions including prefillable syringes, glass vials, plastic packaging, inhalers and diagnostic devices
Latest results
Quarter to September 30, 2026 · EPS €0.61 (estimate €0.27)
Next event
TickerLandia's take on Gerresheimer
- Strong point: Market momentum (90/100 in its group). Weak point: Profitability (1/100).
- “Value traps” (Germany): No. 5 of 12.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−7.72% from the 52-week high
Analysts · 13 analysts
Average target€27.54−12.73% vs. price
Buy 2 · Hold 7 · Sell 4 · Hold
TickerLandia Fingerprint: Gerresheimer
Compared with similar companies: very low profitability, very low price, and very low financial strength.
Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low7
How much it costs relative to what it produces.
Metric Value Position in group Price/book 1.13 1 Price/sales 0.47 1 Forward P/E 12.7 16 EV/EBITDA 10.1 10 Profitabilityvery low1
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 1.6% 1 Gross margin 21.0% 1 ROE −32.4% 1 ROA 0.5% 1 Net margin −17.5% 1 Earnings stabilitylow39
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 2.6% 60 Loss-making yearscounts in reverse: lower means more earnings stability 1 of 5 annual reports 18 Growthaverage59
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +472.84% 95 Average revenue growth (3 years) +8.50% 66 Revenue growth (year over year) −0.80% 16 Financial strengthvery low7
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Current ratio 1.07 22 Interest coverage 1.07 2 Debt/equitycounts in reverse: lower means more financial strength 2.37 5 Net debt/EBITDAcounts in reverse: lower means more financial strength 5.57 2 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong90
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +33.96% 81 Distance from 200-day average +22.75% 95 Relative strength (3 months) +21.46% 94 Relative strength (6 months) +21.63% 88 Riskhigh61
How much the price swings.
Metric Value Position in group Volatility (60 days) 42.5% 85 Beta (1 year) 0.17 6 Maximum drawdown (12 months) 44.2% 90
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Gerresheimer is cheaper than similar companies
Gerresheimer's Forward P/E: 12.7, −38% against the median of a group of 11 similar companies (20.6).
Compared with 11 similar companies
| Metric | Gerresheimer | Position in the group | Band |
|---|---|---|---|
| Forward P/E | 12.7 | Low | |
| Operating margin | 1.6% | Low | |
| ROE | -32.4% | Low | |
| Debt/equity | 2.37 | High | |
| Price/book | 1.13 | Low |
Grey band: the middle half of the group; tick: the median; dot: Gerresheimer. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€474.94M
Latest quarter · Q to Feb 2026
Net income
-€98.32M
Latest quarter · Q to Feb 2026
Quarterly net margin
-20.7%
Latest quarter · Q to Feb 2026
Numbers and valuation
Full valuation- Market cap
- €1.09B
- EPS
- -€11.86
- Volume
- 4.12K
- Daily trading
- €5.01M
How Gerresheimer is changing
All resultsRevenue grew 10.3% a year on average over the last 5 years
Operating margin fell from 10.3% to 4.5%
Shares outstanding up 10.0% in 5 years
Returns
Gerresheimer returns with dividends
€1,000 invested in Gerresheimer 5 years ago, on November 22, 2021, would be worth €407 today with dividends reinvested: −59.25% in total, −16.45% per year. On price alone it would be €391 (−60.89%).
| Period | Gerresheimer | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | −3.66% | −1.98% | €963 |
| 6 months | +21.95% | +0.26% | €1,219 |
| Year to date | +14.43% | +1.28% | €1,144 |
| 1 year | +33.96% | +6.55% | €1,340 |
| 3 years | −62.95% | +55.98% | €370 |
| 5 years | −59.25% | +53.90% | €407 |
| 10 years | −47.35% | +132.12% | €527 |
Over the last 6 months it has done better than 94% of the stocks in the Materials sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Gerresheimer: technical analysis
Gerresheimer is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 74.0% below its all-time closing high (€121.60, September 1, 2023).
- Trend
- Upward
- RSI (14 sessions)
- 51
- Between 30 and 70
- vs 200-session average
- +22.75%
Active signals
The price is moving in an unusually narrow range compared with the last year.
since November 12, 2026
Support and resistance
Price areas where Gerresheimer has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€31.56
- Support€30.15−4.48%4 touches, last on November 6, 2026
- Support€28.27−10.44%4 touches, last on August 19, 2026
- Support€27.47−12.97%3 touches, last on February 10, 2026
Volatility and risk
Over the last year it has moved little with the DAX.
- Beta (1 year) vs DAX
- 0.17
- Volatility (60 sessions, annualised)
- 42.5%
- Largest fall in the last year
- −44.17%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Gerresheimer: seasonality
Average monthly price change over 20 years
Over the last 20 years, the strongest month for Gerresheimer has been April: +5.51% on average, positive in 12 years out of 19. The weakest has been September: −3.60% on average, positive in 7 years out of 20. November, the current month, has been positive in 10 years out of 19 (+2.30% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | −1.50% | 0.00% | 9 of 19 |
| February | +0.54% | −0.86% | 9 of 19 |
| March | −0.62% | −0.21% | 9 of 19 |
| April | +5.51% | +1.43% | 12 of 19 |
| May | +2.25% | +2.47% | 14 of 19 |
| June | −1.53% | +0.29% | 11 of 19 |
| July | +2.87% | +2.67% | 11 of 20 |
| August | +1.84% | +1.85% | 11 of 20 |
| September | −3.60% | −3.22% | 7 of 20 |
| October | −3.21% | −4.51% | 7 of 20 |
| November | +2.30% | +0.20% | 10 of 19 |
| December | −0.53% | +1.95% | 13 of 19 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Gerresheimer and its competitors
Serving customers in Germany and internationally, Gerresheimer AG and its subsidiaries supply drug containment solutions across three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. Its range covers prefillable syringes, vials, glass cartridges and ampoules, plastic and glass packaging, and drug delivery devices such as inhalers and auto injectors, alongside diagnostic and medical products including point-of-care tests, lancing devices and infusion sets.
- Headquarters
- Düsseldorf, Germany
- Employees
- 13,301
- Founded
- 1864
- Chief executive
- Uwe Röehrhoff
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| GerresheimerGXI | $1.19B | 1.6% | — | +21.95% |
| Safilo GroupSFL | $972.72M | 7.2% | 19.1 | +30.89% |
| Bonesupport HoldingBONEX | $2.03B | 25.5% | 78.1 | +25.60% |
| AddLifeALIF.B | $2.11B | 8.9% | 33.5 | +17.73% |
| OttobockOBCK | $2.68B | 18.7% | 19.0 | −31.33% |
| Carl Zeiss MeditecAFX | $3.07B | 7.2% | 23.3 | +24.32% |
Same industry or related industries, similar size. Compare Gerresheimer with its competitors · Full profile
